FULC: Fulcrum Therapeutics, Inc.
Performance
FULC -51.25%
Watchlist
Select an item
Summary
FULC at a glance
FULC returned -51.25% over the past year and -28.51% a year over five years. Its worst drop in that year was -78.49%, smaller than 2% of stocks on Redstone, and its Sharpe ratio of -0.31 beats 16% of stocks on Redstone. It pays no dividends.
Current Drawdown
-74.52%
Rolling Volatility
19.28%
Actions
Metrics
Risk Indicators
Alpha-32.52%
Beta0.44x
Sharpe-0.31
Sortino-0.42
Omega0.93
Calmar-0.65
Martin-0.49
Profile
About FULC
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD).
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $284M
- Listed
- Jul 2019
- Employees
- 55
- Headquarters
- Cambridge, MA
- Website
- fulcrumtx.com
Comparisons